Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA
Taking over the Atlas
Dear Colleagues,
The Atlas, once more, is in great danger, and I will have to proceed to a collective economic lay-off of all the team involved in the Atlas before the begining of April 2015 (a foundation having suddenly withdrawn its commitment to support the Atlas). I ask you herein if any Scientific Society (a Society of Cytogenetics, of Clinical Genetics, of Hematology, or a Cancer Society, or any other...), any University and/or Hospital, any Charity, or any database would be interested in taking over the Atlas, in whole or in part. If taking charge of the whole lot is too big, a consortium of various actors could be the solution (I am myself trying to find partners). Could you please spread the information, contact the relevant authorities, and find partners.
Survival of the Atlas will be critically dependant upon your ability to find solutions (and urgently!).
Kind regards.
Jean-Loup Huret
Donations are also welcome
If each casual visitor gives 3 Euros or Dollars, the Atlas is saved in a week !
If each professional gives 100 Euros or Dollars once a year (now), the Atlas is saved in 2 weeks !
Don't let the Atlas imminent demise
Note: we send fiscal receipts for donations equal or above 50 Euros or Dollars

Donate (in Euros)

Donate (in US Dollars)

MARK4 (MAP/microtubule affinity-regulating kinase 4)


Other namesMARKL1
LocusID (NCBI) 57787
Location 19q13.32
Location_base_pair Starts at 45754516 and ends at 45808541 bp from pter ( according to hg19-Feb_2009)  [Mapping]


Description Spans 55,6 kb; 18 exons
Transcription 3,6kb mRNA of MARK4S isoform, 3,22kb of MARK4L isoform (alternative splicing-skipping of exon 16, which leads to a change in the reading frame ).


Description 688 amino acids (aa) for MARK4S isoform and 752 aa for MARK4L isoform; belongs to the MARK family of protein kinases and contains from aa 59 to 314 a Serine-Threonine kinase catalytic domain with two activating phosphorylation sites. A short sequence (T region) contains a putative membrane-targeting motif. This region is followed by a ubiquitin-associated (UBA) domain. The spacer is the least-conserved region among MARKs proteins. This region is followed by a strikingly conserved C-terminal domain. In MARK4 the C-terminal domain differs between MARK4S and MARK4L isoforms.
Expression The MARK4S isoform is predominantly expressed in the brain and at low levels in the heart. The MARK4L isoform is expressed ubiquitously in all tissues, with a highly abundant expression in testis, neural progenitors and glial tumors. MARK4L is downregulated during glial differentiation.
Localisation Protein was detected homogeneously in cytoplasm.
Function MARK4 is considered to play a role as a messenger of the Wnt-signaling pathway. MARK4L represents a mitogenic-associated isoform.
Homology MARK1, MARK2 (Emk1), MARK3 (p78/C-TAK1), par1, kin1


Note Mutations have not been detected.

Implicated in

Entity Hepatocellular carcinogenesis
Oncogenesis RT-PCR anaysis detected upregulated expression in nearly all clinical hepatocellular carcinoma cells in which nuclear accumulation of b-catenin was observed.
Entity Up-regulation and overexpression of MARK4 has been described in glial tumors and glioblastoma cell lines.
Oncogenesis MARK4 gene activation (enhanced expression and/or amplification) may result from intrachromosomal duplication upon 19q rearrangements.

External links

HGNC (Hugo)MARK4   13538
Entrez_Gene (NCBI)MARK4  57787  MAP/microtubule affinity-regulating kinase 4
GeneCards (Weizmann)MARK4
Ensembl hg19 (Hinxton)ENSG00000007047 [Gene_View]  chr19:45754516-45808541 [Contig_View]  MARK4 [Vega]
Ensembl hg38 (Hinxton)ENSG00000007047 [Gene_View]  chr19:45754516-45808541 [Contig_View]  MARK4 [Vega]
ICGC DataPortalENSG00000007047
Genatlas (Paris)MARK4
SOURCE (Princeton)MARK4
Genomic and cartography
GoldenPath hg19 (UCSC)MARK4  -     chr19:45754516-45808541 +  19q13.2   [Description]    (hg19-Feb_2009)
GoldenPath hg38 (UCSC)MARK4  -     19q13.2   [Description]    (hg38-Dec_2013)
EnsemblMARK4 - 19q13.2 [CytoView hg19]  MARK4 - 19q13.2 [CytoView hg38]
Mapping of homologs : NCBIMARK4 [Mapview hg19]  MARK4 [Mapview hg38]
Gene and transcription
Genbank (Entrez)AB049127 AB058763 AB073663 AB088047 AK027619
RefSeq transcript (Entrez)NM_001199867 NM_031417
RefSeq genomic (Entrez)AC_000151 NC_000019 NC_018930 NT_011109 NW_001838496 NW_004929415
Consensus coding sequences : CCDS (NCBI)MARK4
Cluster EST : UnigeneHs.34314 [ NCBI ]
CGAP (NCI)Hs.34314
Alternative Splicing : Fast-db (Paris)GSHG0015013
Alternative Splicing GalleryENSG00000007047
Gene ExpressionMARK4 [ NCBI-GEO ]     MARK4 [ SEEK ]   MARK4 [ MEM ]
SOURCE (Princeton)Expression in : [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ96L34 (Uniprot)
NextProtQ96L34  [Medical]
With graphics : InterProQ96L34
Splice isoforms : SwissVarQ96L34 (Swissvar)
Catalytic activity : Enzyme2.7.11.1 [ Enzyme-Expasy ] [ IntEnz-EBI ] [ BRENDA ] [ KEGG ]   
Domaine pattern : Prosite (Expaxy)KA1 (PS50032)    PROTEIN_KINASE_ATP (PS00107)    PROTEIN_KINASE_DOM (PS50011)    PROTEIN_KINASE_ST (PS00108)    UBA (PS50030)   
Domains : Interpro (EBI)KA1/Ssp2_C    KA1_dom    Kinase-like_dom    Prot_kinase_dom    Protein_kinase_ATP_BS    Ser/Thr_dual-sp_kinase_dom    Ser/Thr_kinase_AS    UBA/transl_elong_EF1B_N_euk    UBA/Ts_N   
Related proteins : CluSTrQ96L34
Domain families : Pfam (Sanger)KA1 (PF02149)    Pkinase (PF00069)    UBA (PF00627)   
Domain families : Pfam (NCBI)pfam02149    pfam00069    pfam00627   
Domain families : Smart (EMBL)S_TKc (SM00220)  UBA (SM00165)  
DMDM Disease mutations57787
Blocks (Seattle)Q96L34
Human Protein AtlasENSG00000007047
Peptide AtlasQ96L34
IPIIPI00064797   IPI00297959   IPI00020326   IPI00450789   IPI00384052   IPI01013157   
Protein Interaction databases
IntAct (EBI)Q96L34
Ontologies - Pathways
Ontology : AmiGOmicrotubule cytoskeleton organization  microtubule bundle formation  protein serine/threonine kinase activity  protein binding  ATP binding  centrosome  microtubule organizing center  protein phosphorylation  nervous system development  microtubule binding  microtubule cytoskeleton  neuron projection  gamma-tubulin binding  positive regulation of programmed cell death  ubiquitin binding  tau-protein kinase activity  
Ontology : EGO-EBImicrotubule cytoskeleton organization  microtubule bundle formation  protein serine/threonine kinase activity  protein binding  ATP binding  centrosome  microtubule organizing center  protein phosphorylation  nervous system development  microtubule binding  microtubule cytoskeleton  neuron projection  gamma-tubulin binding  positive regulation of programmed cell death  ubiquitin binding  tau-protein kinase activity  
Protein Interaction DatabaseMARK4
DoCM (Curated mutations)MARK4
Wikipedia pathwaysMARK4
Gene fusion - rearrangements
Polymorphisms : SNP, variants
NCBI Variation ViewerMARK4 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)MARK4
Exome Variant ServerMARK4
Genetic variants : HAPMAPMARK4
Genomic Variants (DGV)MARK4 [DGVbeta]
ICGC Data PortalENSG00000007047 
Somatic Mutations in Cancer : COSMICMARK4 
CONAN: Copy Number AnalysisMARK4 
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] 
DECIPHER (Syndromes)19:45754516-45808541
Mutations and Diseases : HGMDMARK4
NextProtQ96L34 [Medical]
Disease Genetic AssociationMARK4
Huge Navigator MARK4 [HugePedia]  MARK4 [HugeCancerGEM]
snp3D : Map Gene to Disease57787
DGIdb (Drug Gene Interaction db)MARK4
General knowledge
Homologs : HomoloGeneMARK4
Homology/Alignments : Family Browser (UCSC)MARK4
Phylogenetic Trees/Animal Genes : TreeFamMARK4
Chemical/Protein Interactions : CTD57787
Chemical/Pharm GKB GenePA30641
Clinical trialMARK4
Cancer Resource (Charite)ENSG00000007047
Other databases
PubMed31 Pubmed reference(s) in Entrez


MAPs, MARKs and microtubule dynamics.
Drewes G, Ebneth A, Mandelkow EM
Trends in biochemical sciences. 1998 ; 23 (8) : 307-311.
PMID 9757832
Isolation of a novel human gene, MARKL1, homologous to MARK3 and its involvement in hepatocellular carcinogenesis.
Kato T, Satoh S, Okabe H, Kitahara O, Ono K, Kihara C, Tanaka T, Tsunoda T, Yamaoka Y, Nakamura Y, Furukawa Y
Neoplasia (New York, N.Y.). 2001 ; 3 (1) : 4-9.
PMID 11326310
Prediction of the coding sequences of unidentified human genes. XX. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.
Nagase T, Nakayama M, Nakajima D, Kikuno R, Ohara O
DNA research : an international journal for rapid publication of reports on genes and genomes. 2001 ; 8 (2) : 85-95.
PMID 11347906
The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines.
Beghini A, Magnani I, Roversi G, Piepoli T, Di Terlizzi S, Moroni RF, Pollo B, Fuhrman Conti AM, Cowell JK, Finocchiaro G, Larizza L
Oncogene. 2003 ; 22 (17) : 2581-2591.
PMID 12735302
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI


Written05-2003Alessandro Beghini


This paper should be referenced as such :
Beghini, A
MARK4 (MAP/microtubule affinity-regulating kinase 4)
Atlas Genet Cytogenet Oncol Haematol. 2003;7(3):162-164.
Free journal version : [ pdf ]   [ DOI ]

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Feb 17 20:33:43 CET 2015

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us